3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
228
Other
4
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms by Site
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
38
Docetaxel
23
Paclitaxel
20
Trastuzumab
19
Cyclophosphamide
18
Gemcitabine
17
Carboplatin
17
Magnetic Resonance Spectroscopy
16
Radiotherapy
14
Nivolumab
13
Radiosurgery
12
Surveys and Questionnaires
11
Specimen Handling
10
Fulvestrant
10
fludarabine
9
aldesleukin
9
Vinorelbine
9
Blood Specimen Collection
9
Taxes
8
Injections
8
Drug Therapy
8
Cisplatin
8
Capecitabine
8
Bevacizumab
8
Standard of Care
7
Psychiatric Rehabilitation
7
Fluorodeoxyglucose F18
7
Early Intervention, Educational
7
sargramostim
6
palbociclib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
exemestane
×
Thoracic
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled